ЭФФЕК ТИВНОСТЬ И БЕЗОПАСНОСТЬ ТОЦИЛИЗУМАБА У ДЕТЕЙ С СИСТЕМНЫМ ВАРИАНТОМ ЮВЕНИЛЬНОГО АРТРИТА В КЛИНИЧЕСКОЙ ПРАКТИКЕ
Аннотация
Представлены результаты проспективного исследования эффективности и безопасности терапии тоцилизумабом (ТЦЗ) системного ювенильного артрита. Проанализировано влияние на эффективность терапии таких факторов, как возраст дебюта заболевания, длительность заболевания на момент начала терапии ТЦЗ, число системных проявлений и активность суставного синдрома, предшествующий опыт применения других генноинженерных биологических препаратов. Кроме того, проведен анализ безопасности длительного применения ТЦЗ, причин отмены и возможности возобновления терапии, путей повышения эффективности лечения.
Об авторах
М. И. КаледаРоссия
Контакты: Мария Игоревна Каледа; kaleda-mi@yandex.ru
И. П. Никишина
Россия
Список литературы
1. Л И Т Е Р А Т У Р А
2. Cassidy JT. Juvenile rheumatoid arthritis. In: Cassidy JT, Petty RE, editors. Textbook of pediatric rheumatology. 4th edition. Philadelphia: W.B. Saunders Company; 2001. P. 218–322.
3. Алексеева ЕИ, Литвицкий ПФ. Ювенильный ревматоидный артрит: этиология, патогенез, клиника, алгоритмы диагностики и лечения. Руководство для врачей, преподавателей, научных сотрудников. Под общей редакцией А.А. Баранова. Москва: ВЕДИ; 2007. 368 с. [Alekseeva EI, Litvitskii PF. Yuvenil'nyi revmatoidnyi artrit: etiologiya, patogenez, klinika, algoritmy diagnostiki i lecheniya. Rukovodstvo dlya vrachei, prepodavatelei, nauchnykh sotrudnikov [Juvenile rheumatoid arthri- tis: etiology, pathogenesis, clinical features, diagnosis and treatment algorithms. Guidelines for doctors, teachers, researchers]. Baranov AA, editor. Moscow: VEDI; 2007. 368 p.].
4. Sawhney S, Woo P, Murrey KJ. Macrophage activation syndrome: A potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001;85(5):421–6. doi: 10.1136/adc.85.5.421
5. De Benedetti F, Massa M, Robbioni P, et al. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991;34:1158–63. doi: 10.1002/art.1780340912
6. Cazzola M, Ponchio L, de Benedetti F, et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin pro- duction in the anemia associated with systemic-onset juvenile chronic arthritis. Blood. 1996;87(11):4824–30.
7. De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthri- tis an interleukin 6 mediated disease? J Rheumatol. 1998;25(2):203–7.
8. Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5:1731–40. doi: 10.1016/j.intimp.2005.05.010
9. Yokota S, Miyamae T, Imagawa Т, et al. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis. Clin Rev Allergy Immunol. 2005;28:231–8. doi: 10.1385/CRIAI:28:3:231
10. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, with- drawal phase III trial. Lancet. 2008;371:998–1006. doi: 10.1016/S0140-6736(08)60454-7
11. Yokota S, Imagawa T, Miyamae T. Safety and efficacy of up to three years of continuous tocilizumab therapy in children with sys- temic-onset juvenile idiopathic arthritis [SAT0536]. Ann Rheum Dis. 2009; 68 Suppl 3:715.
12. Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the effi- cacy of IL-6 receptor blockade in this type of arthritis and demon- stration of prolonged clinical improvement. Arthritis Res Ther. 2005;7:R1281–8. doi: 10.1186/ar1826
13. De Benedetti F, Brunner H, Allen R, et al. Tocilizumab Is effica- cious in patients with systemic juvenile idiopathic arthritis across baseline demographic and disease characteristics and prior/base- line treatments: 52-week data from a phase 3 clinical trial. Arthritis Rheum. 2011;63 Suppl:S1029–30.
14. De Benedetti F, Brunner H, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–95. doi: 10.1056/NEJMoa1112802.
15. Petty RE, Southwood TR, Manners P, et al; International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004 Feb;31(2):390–2.
16. Reiff A. Treatment of systemic juvenile idiopathic arthritis with tocilizumab – the role of anti-interleukin-6 therapy after a decade of treatment. Biol Ther. 2012 Feb 1;2:1. eCollection 2012. doi: 10.1007/s13554-012-0001-6
17. Баранов АА, Алексеева ЕИ, Денисова РВ и др. Ретроспективный анализ эффективности и безопасности тоцилизумаба у больных тяжелым системным ювенильным идиопатическим артритом: 12 месяцев наблюдения. Вопросы современной педиатрии. 2013;12(2):26–34. [Baranov AA, Alekseeva EI, Denisova RV, et al. Retrospective analysis of efficacy and safety of tocilizumab in patients with severe systemic juvenile idiopathic arthritis: 12 months follow-up. Voprosy sovremennoi pediatrii. 2013;12(2):26–34. (In Russ.)].
18. Alexeeva EI, Baranov AA, Valieva SI, et al. Retrospective analysis of efficacy and safety of tocilizumab treatment in patients with severe systemic-onset juvenile idiopathic arthritis followed for 12 months. ISRN Immunology Volume. 2013(2013),Article ID 548312, 8 p. doi: 10.1155/2013/548312
19. De Benedetti F, Ruperto N, Baildam E, et al. A14: Neutropenia with tocilizumab treatment is not associated with increased infec- tion risk in patients with systemic juvenile idiopathic arthritis. Arthritis Rheum. 2014;66:S23–4. doi: 10.1002/art.38430
20. Malattia C, Ruperto N, Palmisani E, et al. Assessment of radi- ographic progression in patients with systemic juvenile idiopathic arthritis treated with tocilizumab: 2-year results from the TENDER Trial. Arthritis Rheum. 2014 Mar;66 Suppl 11:S96–7. doi: 10.1002/art.38482
21. Aoki C, Inaba Y, Choe H, et al. Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis. J Rheumatol. 2014;41:1171–7. doi: 10.3899/jrheum.130924
22. Шаповаленко АН, Никишина ИП, Шарова АА. Проблема нарушения роста у больных ювенильными артритами. Научно-практическая ревматология. 2007;(5):74–82. [Shapovalenko AN, Nikishina IP, Sharova AA. The problem of dysplasia in patients with juvenile arthritis. Nauchno-praktich- eskaya revmatologiya = Rheumatology Science and Practice. 2007;(5):74–82. (In Russ.)].
23. Kessler E, Vora S, Verbsky J. Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome. Pediatr Rheumatol Online J. 2012 Aug 29;10(1):30. doi: 10.1186/1546- 0096-10-30
24. Ravelli A, Schneider R, Weitzman S, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with tocilizumab. Arthritis Rheumatol. 2014 Mar;66 Suppl 11:S83–4. doi: 10.1002/art.38472
25. Митенко ЕВ, Алексеева ЕИ, Денисова РВ, Слепцова ТВ. Клинический случай применения тоцилизумаба у пациентки с системным ювенильным идиопатическим артритом. Педиатрическая фармакология. 2013;(4):154–8. [Mitenko EV, Alekseeva EI, Denisova RV, Sleptsova TV. Clinical case of the use of tocilizumab in patients with systemic juvenile idiopathic arthritis. Pediatricheskaya farmakologiya. 2013;(4):154–8. (In Russ.)].
Для цитирования:
Каледа М.И., Никишина И.П. ЭФФЕК ТИВНОСТЬ И БЕЗОПАСНОСТЬ ТОЦИЛИЗУМАБА У ДЕТЕЙ С СИСТЕМНЫМ ВАРИАНТОМ ЮВЕНИЛЬНОГО АРТРИТА В КЛИНИЧЕСКОЙ ПРАКТИКЕ. Научно-практическая ревматология. 2015;53(2):204-213. https://doi.org/10.14412/1995-4484-2015-204-213
For citation:
Kaleda M.I., Nikishina I.P. EFFICACY AND SAFETY OF TOCILIZUMAB IN CHILDREN WITH SYSTEMIC JUVENILE ARTHRITIS IN CLINICAL PRACTICE. Rheumatology Science and Practice. 2015;53(2):204-213. (In Russ.) https://doi.org/10.14412/1995-4484-2015-204-213